Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Cancer

Prostate cancer

MicroRNA-23b (miR-23b)

Patient sample and mouse studies suggest increasing miR-23b signaling could help treat prostate cancer. In patient samples, miR-23b expression was lower in prostate cancer tissue than in benign prostatic hyperplasia and normal tissue. In a mouse xenograft model of prostate cancer, intratumoral delivery of miR-23b decreased tumor growth compared with delivery of control miRNA. Next steps could include evaluating vehicles for targeted delivery of miR-23b in prostate cancer models.

SciBX 5(44); doi:10.1038/scibx.2012.1157
Published online Nov. 8, 2012

Patent and licensing status unavailable

Majid, S. et al. Cancer Res.;
published online Oct. 16, 2012;
doi:10.1158/0008-5472.CAN-12-2181
Contact: Rajvir Dahiya, San Francisco VA Medical Center and University of California, San Francisco, Calif.
e-mail:
rdahiya@urology.ucsf.edu